Breast Cancer

Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.

The United States Preventive Services Task Force final breast cancer screening recommendation statement advises that women aged 40 begin biennial screening.

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, emphasize the importance of shared decision-making, comprehensive data, and well-informed multidisciplinary team collaboration in delivering high-quality, patient-centered care, while highlighting the benefits of tailored adjuvant therapies.

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.

Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Trastuzumab deruxtecan improved PFS vs chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.

The EMA’s CHMP recommended capivasertib/fulvestrant for ER-positive, HER2-negative advanced breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

Rita Nanda, MD, discusses the evolution of treatment with CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

Medical professionals discuss proactive symptom management for adverse events like diarrhea, hair thinning, cytopenia, and neutropenia, offering guidance on dose reduction and treatment holds to optimize patient outcomes while minimizing adverse effects.

Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.

Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.

Rita Nanda, MD, discusses the evolution of treatment options for patients with HER2-low breast cancer.

Siddartha Yadav, MD, FACP, of Mayo Clinic, discusses personalizing treatment for patients with germline–mutant contralateral breast cancer.

Nan Chen, MD, discusses the investigation of CDK4/6 inhibitors in early-stage breast cancer.

The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.

Medical experts analyze the impact of CDK4/6 inhibitors in early-stage HR+/Her2- breast cancer patients, and how recent clinical trial data translates to the real-world clinical application of these agents.

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses the current use of neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer.

Anne Favret, MD discusses the evolution of treatment with endocrine-based combination therapies in HR-positive/HER2-negative metastatic breast cancer.

The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.

Ko Un “Clara” Park, MD discusses the assessment of robot-assisted nipple sparing mastectomy in breast cancer.

Erin Frances Cobain, MD, on second-line treatment options for patients with HR-positive, HER2-negative metastatic breast cancer.

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide an in-depth analysis of the randomized phase III monarchE trial, which focused on Abemaciclib in high-risk early-stage HR+, HER2- breast cancer, offering insights into recurrence rates, progression-free survival, and distant disease-free survival outcomes for patients.

Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.